CIN: L24239AP2002PLC039449

August 14, 2019

To

Corporate Relations Department, BSE LTD, P J Towers, Dalal Street, Mumbai - 400001.

Sirs,

Sub: Q1 Unaudited Financial Results – Reg...

Ref: Scrip Code – 532905

Please find herewith attached Un-audited financial results for the first quarter ending 14<sup>th</sup> August 2019 along with Limited Review Report. The Board Meeting Commenced at 4 PM and concluded at 5:15 PM. Please take on record the same.

Thanking You,

For SAAMYA BIOTECH (INDIA) LIMETAN

Director

Regd. Office: #104-106, Lumbini Enclave, 6-3-665, Opp. NIMS, Punjagutta, Hyderabad - 82, Telangana, India, Ph: +91-40-2339 2099 / 3099 / 8099 Web: www.saamyabiotech.net; Email: saamyaindia@saamyabiotech.net



## Saamya Biotech (India) Ltd.

	SAAMYA BIOTECH (IN	DIA) LIMITED			
C 21	Statement of Un-Audited Results for the		d 30.06.2019		1 1
S.No.	Particulars	For the	For the	For the	For the year
		Quarter	Quarter	Quarter ended	ended
	a *	ended	ended	30.06.2018	31.03.2019
		30.06.2019	31.03.2019		
	7	Un audited	Audited	Un audited	Audited
I.	Revenue from Operations	-	-	-	
II.	Other Income		-	-	
	Total income (I+II)	-	-	-	14
IV.	Expenses	7		•	
	(a) Cost of Materials consumed	2 -		-	
	(b) Purchase of stock-in-trade	-	٠	)-	
	(c) Changes in inventories of finished goods, work-in-progress	-			
	(d) Employee benefits expense	0.25	0.15	0.36	0.9
	(e) Finance Cost	_	-		
	(f) Depreciation and amortisation expense	_			
	(h)Other expenses	0.25	0.10	0.25	1.0
	Total Expenses	0.50	0.25	0.61	1.9
V.	Profit / (Loss) before and exceptional items and Tax ( III-IV)	(0.50)	(0.25)	(0.61)	
VI.	Exeptional Items	(0.50)	(0.23)	(0.01)	(1.9
	Profit / (Loss) from before tax (V-VI)	(0.50)	(0.25)	(0.61)	(1.0
VIII.	Tax expense	(0.50)	(0.23)	(0.01)	(1.9
	Current Tax				
	Deferred Tax				
IX.	Net Profit / (Loss) after Tax (VII-VIII)	(0.50)	(0.25)	(0.61)	
X	Other Comprehensive Inocme	(0.30)	(0.25)	(0.61)	(1.90
80 (8)	Items that will not be reclasified to Profit or Loss				
	Items that will be reclasified to Profit or Loss				
ΧI	Total Comprehensive Income	(0.50)	(0.25)	49.44	- 4
XII	Paid-up equity share capital	(0.50)	(0.25)	(0.61)	(1.96
	(Face Value of Rs. 10/- per share)	2,488.25	2 400 25		
	Earnings Per Equity Share of face value of Rs.10/- each)	4,400,25	2,488.25	2,488.25	2,488.2
	a) Basic & Diluted (In Rs.)	(0.002)	(0.001)		
	Ly David & Diluted ( III No.)	(0.002)	(0.001)	(0.002)	(0.01

## NOTES:

In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been prepared, reviewed by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on on 12.08.2019

The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).

These results have been prepared in accordance with the recognition and measurent principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with teh relevant rules issued thereunder and other accouting propouncements generally accepted in India.

The results are also available on the webiste of the Company www.saamyabiotechltd.com

The Company is engaged in "Research and Development of Bio-technology Products" operating hence there are no separate reportable segments as per Ind AS -108

For SAAMYA BIOTECH (INDIA) L

MANIVARDHAN REDDY YALA **Wholetime Director** 

Din (01368438)

Place: Hyderabad Date: 12.08.2019

> Regd. Office: #104-106, Lumbini Enclave, 6-3-665, Opp. NIMS, Punjagutta, Hyderabad - 82, Telangana, India, Ph: +91-40-2339 2099 / 3099 / 8099 Web: www.saamyabiotech.net; Email: saamyaindia@saamyabiotech.net



## M M REDDY & CO.,

Chartered Accountant

Phone: 040-65536097

Fax: 040-23478836 Mobile: 98482 71555

91770 20555

## LIMITED REVIEW REPORT

To,
The Board of Directors,
SAAMYA BIOTECH (INDIA) LTD

We have reviewed the accompanying statement of Un-audited Financial Results of SAAMYA BIOTECH (INDIA) LTD or the quarter ended 30<sup>th</sup> June, 2019 attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M M Reddy & Co. Chartered Accounting

Chartered

M Madhusudhana Partner

Membership No. 21307

CFOSMOTARAFFOEISPI:ON NIDU

Place: Hyderabad

Date: 14th August, 2018.

